Mesenchymal Stem Cell Production via Cytokine-Free Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for inducing mesenchymal stem cells from human pluripotent stem cells are inefficient, costly, and prone to risks such as carcinogenesis, immunological rejection, and tumorigenesis, with existing methods requiring specific cytokines, xeno feeders, and complex differentiation procedures, limiting their use in regenerative medicine and cell therapy.
Innovation Solution
A method involving culturing human pluripotent stem cells in a suspension state without bFGF for 14 days to form embryonic bodies, which are then differentiated into mesenchymal stem cells in Dulbecco's Modified Eagle's Medium with fetal bovine serum without external cytokines, using a medium containing growth factors like hEGF, VEGF, and hFGF-B for prolonged proliferation and maintaining mesenchymal stem cell identity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If specific cytokines (BMP, bFGF) are used for induction, then differentiation efficiency is improved, but production cost increases and process complexity increases
Solution Approach 1:
The patent removes the requirement for external cytokine supplementation (BMP, bFGF) from the culture medium, extracting the harmful complexity while maintaining differentiation efficiency through the optimized base medium composition containing specific growth factors and cytokines at controlled concentrations
Solution Approach 2:
The patent optimizes the concentrations of growth factors (EGF: 20-100 ng/mL, FGF-basic: 20-100 ng/mL, IGF-1: 10-50 ng/mL) and cytokines (hydrocortisone: 0.1-1 µM, ascorbic acid: 50-200 µM) in the culture medium to achieve high differentiation efficiency without requiring additional external cytokine additions, thereby simplifying the process
2Reliability
If xeno feeders (OP9 mouse cell lines) are used for induction, then differentiation capability is improved, but risk of xeno pathogen transmission increases
Solution Approach 1:
The patent completely eliminates the use of xeno feeders (OP9 mouse cell lines) from the differentiation process, removing the source of xeno pathogen risk while maintaining high differentiation capability through the optimized serum-free culture medium containing specific growth factors and cytokines
Solution Approach 2:
The patent replaces the use of living xeno feeder cells with a defined, serum-free culture medium formulation that provides necessary growth factors and cytokines, eliminating the need for animal-derived components and associated pathogen risks
3Manufacturing precision
If sorting by specific marker (CD73) is performed, then cell purity is improved, but production time increases and process complexity increases
Solution Approach 1:
The patent removes the sorting step by specific marker (CD73) from the production process, eliminating the time loss and process complexity associated with flow cytometry sorting, while achieving high cell purity through optimized culture conditions that promote selective mesenchymal stem cell differentiation and survival
Solution Approach 2:
The patent enables the culture system to automatically select and enrich for mesenchymal stem cells through the optimized medium composition, where the specific growth factors and cytokines create an environment that favors the survival and proliferation of desired cell types without requiring external sorting intervention
4Reliability
If human pluripotent stem cells are used to produce mesenchymal stem cells, then immunological rejection risk is reduced, but differentiation efficiency decreases and production cost increases
Solution Approach 1:
The patent optimizes the concentrations of growth factors (EGF: 20-100 ng/mL, FGF-basic: 20-100 ng/mL, IGF-1: 10-50 ng/mL) and cytokines (hydrocortisone: 0.1-1 µM, ascorbic acid: 50-200 µM) in the serum-free culture medium to achieve high differentiation efficiency from human pluripotent stem cells while maintaining immunological compatibility
Data Source
Figure 1a~1c
Figure 2a~2d
Figure 3~4b
AI summary
Provided is a method for producing mesenchymal stem cells from human pluripotent stem cells, the method including: a) forming embryonic bodies from human pluripotent stem cells; b) attaching the embryonic bodies to a culture dish to induce natural differentiation of the embryonic bodies into mesenchymal stem cells; and c) performing continuous proliferative culturing of the mesenchymal stem cells while still maintaining the identity of the mesenchymal stem cells. Also, provided is a standardized method for inducing differentiation of mesenchymal stem cells, which can be broadly applied to all human pluripotent stem cells regardless of a difference in the genetic background thereof. Ultimately, the present invention can continuously mass-produces the mesenchymal stem cells necessary for regenerative medicine and cell therapy by using human pluripotent stem cells, thereby realizing practical uses of cell therapy products, and further the present invention is expected to highly contribute to treatments of incurable diseases, such as cardiovascular diseases and neurological disorders.